Dr David Dodwell
BSc, MD, FRCP, FRCR
Senior Clinical Research Fellow
I am a senior breast oncologist based in Leeds with a number of research and governance activities. I am the lead oncologist on the Sloane, NHS screening & national HQIP breast cancer audits.
I am a senior clinical research fellow to the EBCTCG and a member of steering groups for 12 ongoing UK trials in breast cancer. I sit on the trial management committees for 3 trials.
I am UK lead for the SACT project (UK chemotherapy database) and chair the clinical group, which provides input and advice to this project to examine the safety, efficacy and cost-effectiveness of chemotherapy used in England.
Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.
Thompson AM. et al, (2018), European journal of cancer (Oxford, England : 1990), 101, 210 - 219
Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation surgery?
Bagenal J. et al, (2018), BMJ, 361
Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ.
Maxwell AJ. et al, (2018), Eur J Surg Oncol, 44, 429 - 435
Neoadjuvant chemotherapy for early breast cancer - Author's reply.
McGale P. et al, (2018), Lancet Oncol, 19
Impact of radiotherapy and endocrine therapy on further events: Final multivariate analysis of a prospective, national cohort study of screen detected ductal carcinoma in situ (DCIS) of the breast
Thompson AM. et al, (2018), CANCER RESEARCH, 78